Survival of gynecological cancers in Turkey: where are we at?

Abstract

ObjectiveTo investigate the 5-year relative survival rates in gynecological cancers diagnosed and treated in Turkey by year 2009 and to compare the results with developed countries.MethodsData of patients diagnosed for ovarian, corpus uteri or cervix uteri cancer at year 2009 are collected from 9 national cancer registry centers. Date of deaths are retracted from governmental Identity Information Sharing System (KPS). In order to calculate relative survival rates, national general population mortality tables are obtained from Turkish Statistical Institute (TurkStat). Hakulinen method is used for computing curves by R program. Data for European, Asian and some developed countries were obtained from official web pages.ResultsA total of 1,553 patients are evaluated. Among these, 713 (45.9%) are corpus uteri cancers, while remaining 489 (31.5%) are ovarian and 351 (22.6%) are cervix uteri. Five-year overall relative survival rates are 85%, 50%, and 62% for corpus uteri, ovarian, and cervix uteri, respectively. These figures are between 73%–87% for corpus uteri, 31%–62% for ovarian and 61%–80% for cervix uteri in developed countries. Stage is the most important factor for survival in all cancers. Five-year relative survival rates in corpus uteri cancers are 92%, 66%, and 38% for localized, regional, and distant metastatic disease, respectively. These figures are 77%, 57%, and 29% for ovarian; 80%, 50%, and 22% for cervix uteri.ConclusionThis is the first report from Turkey giving national overall relative survival for gynecological cancers from a population based cancer registry system.

Histo-epidemiological aspects of gynecological and breast cancers at the University Teaching Hospital of Yaoundé

“…Endometrial cancer was third most common cancer in our series, accounting for 9.7%; this result is similar to that of Engbang et al who found 11.6% in 2015 in the Littoral region of Cameroon and Agboeze et al found a proportion of 10.1% in Nigeria in 2015 [6, 13]. This proportion, however, is lower than those found in developed countries, especially the 40.1% reported in Japan by Yamagami et al in 2017 and 45.9% in Turkey according to Gultekin et al in 2017 [14, 15]. This difference could be explained by the fact that, unlike cervical cancer, where screening methods are known and screening programs are operational and effective in these countries, there is no method of screening for endometrial cancer.…”

Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis

“…All patients were staged according to the SEER stage (localized, regional, and distant). According to SEER rules, cervix uteri FIGO stage I; FIGO stages II, III; and FIGO stage IV are classified as localized, regional, and distant disease [ 15 16 ]. We also used X-tile 3.6.1 software (Yale University, New Haven, CT, USA) to transform the value of the age at diagnosis into a categorical variable ( Supplementary Fig.…”

2009-2013 YILLARI ARASINDA TAKSİM-GAZİOSMANPAŞA EĞİTİM ve ARAŞTIRMA HASTANESİNDE OPERE EDİLEN JİNEKOLOJİK MALİGNİTE VAKALARININ RETROSPEKTİF DEĞERLENDİRİLMESİ

“…Bu nedenle ek olarak fertilitenin korunması gibi özel durum ve güçlükleri de bünyesinde barındırır. 2012 yılı itibari ile serviks, corpus uteri ve over kanserleri tüm kadın kanserlerinin %16'sını, kanser nedenli ölümlerin %14'ünü teşkil eder (2). Yaş, enfeksiyöz nedenler (human papilloma virus, human immunodeficiency virus, diğer cinsel yolla bulaşan enfeksiyözler), reprodüktif ve hormonal nedenler (menarş, menapoz, doğum sayısı, emzirme, koit yaşı, partner durumu, endojen hormonal ajanlar vb), sigara, önceki kanserler, medikal durum ve alınan tedaviler, obezite, immun sistem durumu, aile öyküsü-genetik gibi çok sayıda etken jinekolojik kanser etyolojisi içinde yer almaktadır.…”

“…), human papillomavirus (HPV) aşı programları, erken belirtilerin tanınmasına olanak sağlayacak önlemler (tarama programları gibi) ile önlenebilir veya erken tanı alabilir. Araştırmamızda 2009-2013 yılları arasında kliniğimizde opere edilen jinekolojik malignitelerin orijin, yaş dağılımı, evre dağılımı, bazı epidemiyolojik özellikler açısından retrospektif değerlendirilmesi amaçlanmıştır (2).…”